Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Prudential Financial Inc.

Prudential Financial Inc. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,733 shares of the specialty pharmaceutical company's stock after purchasing an additional 8,352 shares during the quarter. Prudential Financial Inc. owned about 0.12% of Supernus Pharmaceuticals worth $2,374,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Smartleaf Asset Management LLC lifted its position in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after buying an additional 870 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth $72,000. Venturi Wealth Management LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at about $92,000. KBC Group NV grew its holdings in shares of Supernus Pharmaceuticals by 53.1% in the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock valued at $97,000 after purchasing an additional 929 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $211,000.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SUPN shares. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Remove Ads

Insider Buying and Selling

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company's stock, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company's stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Trading Down 5.1 %

SUPN traded down $1.63 on Tuesday, hitting $30.64. The company had a trading volume of 641,507 shares, compared to its average volume of 488,643. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The firm has a market cap of $1.71 billion, a P/E ratio of 28.64 and a beta of 0.90. The company's fifty day moving average price is $34.09 and its 200 day moving average price is $35.04.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.